Trial · NCT05856760

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

NCT05856760, Phase 2, Completed, Travere Therapeutics, Inc.; results first posted 2025-11-20

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN. Trials, record NCT05856760. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05856760

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
NCT number: NCT05856760
Status: Completed
Phases: Phase 2
Enrollment: 48 participants, actual
Lead sponsor: Travere Therapeutics, Inc.
Conditions: Immunoglobulin A Nephropathy
Interventions: Sparsentan
First posted: 2023-05-12
Last updated: 2025-11-20
Results first posted: 2025-11-20

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24	Week 24	The change from baseline in UA/C at Week 24 based on first morning void (FMV) samples
Secondary	UA/C <0.2 g/g at Week 24	Week 24	Achievement of UA/C of \<0.2 g/g at Week 24 based on FMV samples
Secondary	30% Reduction From Baseline in UA/C at Week 24	Week 24	Achievement of 30% reduction from baseline in UA/C at Week 24 based on FMV samples
Secondary	50% Reduction From Baseline in UA/C at Week 24	Week 24	Achievement of 50% reduction from baseline in UA/C at Week 24 based on FMV samples
Secondary	Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24	Week 24	The change from baseline in UP/C at Week 24 based on FMV samples
Secondary	Estimated Glomerular Filtration Rate (eGFR)	Week 24	Change from baseline estimated glomerular filtration rate at 24 weeks
Secondary	Systolic Blood Pressure (BP) at Week 24	Week 24	The change from baseline in systolic BP at Week 24
Secondary	Change in Diastolic Blood Pressure (BP)	Week 24	The change from baseline in diastolic BP at Week 24

Source ClinicalTrials.gov

Outcomes8

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24	Week 24	Full Analysis Set	percent change	LEAST_SQUARES_MEAN
SECONDARY	UA/C <0.2 g/g at Week 24	Week 24	Full Analysis Set	percentage of participants	NUMBER
SECONDARY	30% Reduction From Baseline in UA/C at Week 24	Week 24	UA/C Responder Endpoints While on Treatment	percentage of participants	NUMBER
SECONDARY	50% Reduction From Baseline in UA/C at Week 24	Week 24	Full Analysis Set	percentage of participants	NUMBER
SECONDARY	Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24	Week 24	Full Analysis Set	percentage change	LEAST_SQUARES_MEAN
SECONDARY	Estimated Glomerular Filtration Rate (eGFR)	Week 24	Full Analysis Set	mL/min/1.73 square meter	GEOMETRIC_MEAN
SECONDARY	Systolic Blood Pressure (BP) at Week 24	Week 24	Full Analysis Set	mmHg	LEAST_SQUARES_MEAN
SECONDARY	Change in Diastolic Blood Pressure (BP)	Week 24	Full Analysis Set	mmHg	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in Urine Albumin-creatinine Ratio (UA/C) at Week 24	Sparsentan	-55.78	95% Confidence Interval -65.8 to -42.8	percent change
UA/C <0.2 g/g at Week 24	Sparsentan	31	95% Confidence Interval 17.0 to 47.6	percentage of participants
30% Reduction From Baseline in UA/C at Week 24	Sparsentan	77	95% Confidence Interval 60.7 to 88.9	percentage of participants
50% Reduction From Baseline in UA/C at Week 24	Sparsentan	51	95% Confidence Interval 34.8 to 67.6	percentage of participants
Change in Urine Protein-to-creatinine Ratio (UP/C) at Week 24	Sparsentan	-45.20	95% Confidence Interval -54.6 to -33.9	percentage change
Estimated Glomerular Filtration Rate (eGFR)	Sparsentan	-2.0	95% Confidence Interval -3.9 to -0.1	mL/min/1.73 square meter
Systolic Blood Pressure (BP) at Week 24	Sparsentan	-3.4	95% Confidence Interval -6.8 to 0.0	mmHg
Change in Diastolic Blood Pressure (BP)	Sparsentan	-4.6	95% Confidence Interval -6.7 to -2.4	mmHg

Source ClinicalTrials.gov

Participant flow4

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Sparsentan	48
Overall Study	Discontinued	Sparsentan	7
Overall Study	COMPLETED	Sparsentan	41
Overall Study	NOT COMPLETED	Sparsentan	7

Source ClinicalTrials.gov

Adverse events11

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Hypotension	Vascular disorders	Sparsentan	7	48
other	Headache	Nervous system disorders	Sparsentan	4	48
other	Oedema	General disorders	Sparsentan	4	48
other	Oedema peripheral	General disorders	Sparsentan	4	48
other	Upper respiratory tract infection	Infections and infestations	Sparsentan	4	48
other	Dizziness	Nervous system disorders	Sparsentan	3	48
serious	Osteoarthritis	Musculoskeletal and connective tissue disorders	Sparsentan	1	48	1
serious	Cerebrovascular event	Nervous system disorders	Sparsentan	1	48	1
serious	Acute kidney injury	Renal and urinary disorders	Sparsentan	1	48	1
serious	Deep vein thrombosis	Vascular disorders	Sparsentan	1	48	1

1 to 10 of 11Source ClinicalTrials.gov

See all 11 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sparsentan	0	48
Total, other adverse events	Sparsentan	26	48
Total, serious adverse events	Sparsentan	4	48

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05856760

GET https://conductscience.org/api/trials/v1/NCT05856760/registered

API reference For AI assistants